A-Alpha Bio Collaborates with Amgen to Enable Molecular Glue Discovery

We’re thrilled to announce that A-Alpha Bio is expanding our collaboration with Amgen! On the heels of a successful collaboration with Amgen that began in 2022, we announced this morning that we will be expanding our partnership to progress further toward the rational discovery of molecular glues. 

Over the past six months, A-Alpha Bio discovered several weak interactions between targets selected by Amgen and a panel of E3 ubiquitin ligases – indicating that it may be possible to induce target degradation by enhancing binding with a small molecule. Following additional work by Amgen to validate newly identified ligase-target pairings, we have now expanded our collaboration to further interrogate selected pairs and provide insights expected to enable rational design of molecular glue degraders. 

Combining our technology and expertise with Amgen’s has been a privilege. We’re thrilled to continue collaborating with an industry leader to enable the discovery of high-impact molecular glue therapeutics and advance our mission to improve human health.

You can learn more about our expanded collaboration with Amgen here.